Regencell Posts $3.58M Loss, Eyes ADHD/ASD TCM Approval

TL;DR

**RGC is a speculative bet on unproven TCM for ADHD/ASD, burning cash with no revenue or approvals; avoid until clinical milestones are met.**

AI Summary

Regencell Bioscience Holdings Ltd (RGC) reported net losses of $3.58 million for the fiscal year ended June 30, 2025, following a $4.36 million net loss in fiscal year 2024, reflecting its status as an early-stage Traditional Chinese Medicine (TCM) bioscience company with no revenue from product sales. The company's operations are primarily funded by proceeds from its initial public offering. A significant business change occurred on June 13, 2025, with a 38-for-1 forward stock split, resulting in 481,476,042 additional ordinary shares, bringing the total outstanding to 494,488,908 ordinary shares. This reclassification did not alter the authorized share capital of $1,000,000 or the par value of $0.00001 per share. Key risks include the ongoing development of its standardized TCM formula for ADHD and ASD, the absence of regulatory approvals or granted patents, and the need for substantial additional financing to fund future research, development, and potential commercialization efforts. The strategic outlook is focused on completing research studies, obtaining regulatory approvals in Hong Kong and other jurisdictions, and establishing manufacturing and distribution capabilities for its TCM formula.

Why It Matters

Regencell's continued losses and lack of revenue highlight the inherent risks of early-stage bioscience investments, particularly in the unproven Traditional Chinese Medicine space for neurocognitive disorders. For investors, the success hinges entirely on future regulatory approvals and commercialization, which are highly uncertain and capital-intensive. Employees and customers face uncertainty given the company's developmental stage and absence of approved products. In the broader market, Regencell's approach to ADHD and ASD with TCM could offer a novel alternative if successful, but it faces significant competition from established pharmaceutical treatments and a high bar for regulatory acceptance.

Risk Assessment

Risk Level: high — Regencell is an early-stage TCM bioscience company with a limited operating history, incurring net losses of $3.58 million in fiscal year 2025 and $4.36 million in fiscal year 2024. The company has no saleable products, no revenue from product sales, and no granted patents or pending patent applications, indicating a high degree of operational and financial uncertainty.

Analyst Insight

Investors should exercise extreme caution and consider Regencell a highly speculative investment. Monitor for concrete progress in research studies, successful regulatory filings, and securing substantial additional financing, as the company's current trajectory indicates significant capital needs without a clear path to profitability.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$3.58M

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Key Numbers

• $3.58M — Net Loss (For the fiscal year ended June 30, 2025, following a $4.36 million loss in 2024.)
• $4.36M — Net Loss (For the fiscal year ended June 30, 2024.)
• 494,488,908 — Ordinary Shares Outstanding (As of June 30, 2025, after a 38-for-1 forward stock split.)
• 38-for-1 — Forward Stock Split Ratio (Implemented on June 13, 2025, increasing outstanding shares.)
• $0.00001 — Par Value per Ordinary Share (Remained unchanged after the stock split.)
• $1,000,000 — Authorized Share Capital (Remained unchanged after the stock split.)
• July 16, 2021 — Nasdaq Listing Date (Date RGC Ordinary Shares began trading on Nasdaq Capital Market.)

Key Players & Entities

• Regencell Bioscience Holdings Ltd (company) — Registrant
• Yat-Gai Au (person) — Chief Executive Officer
• Sik-Kee Au (person) — Strategic TCM research partner and father of CEO
• Nasdaq Capital Market (company) — Stock exchange where RGC is listed
• SEC (regulator) — Securities and Exchange Commission
• Hong Kong (regulator) — Jurisdiction for initial regulatory approval
• ADHD (other) — Neurocognitive disorder targeted by TCM formula
• ASD (other) — Neurocognitive disorder targeted by TCM formula

FAQ

Risk Factors

• Limited Operating History and Incurrence of Losses [high — financial]: Regencell is an early-stage TCM bioscience company with no approved products or revenue from sales. The company incurred net losses of $3.58 million for FY2025 and $4.36 million for FY2024, primarily due to development and general administrative costs. Significant future expenses are anticipated for research, development, potential commercialization, and regulatory approvals.
• Substantial Additional Financing Required [high — financial]: The company has funded operations through its IPO proceeds and expects to continue incurring losses. Substantial additional financing will be necessary to fund future research, development, potential commercialization, and regulatory efforts, indicating a high reliance on external capital.
• Absence of Regulatory Approvals and Patents [high — regulatory]: Regencell has not yet obtained any regulatory approvals for its TCM formula for ADHD and ASD, nor have any patents been granted. This lack of approval and intellectual property protection poses a significant risk to the company's ability to commercialize its products.
• Dependence on Development of Standardized TCM Formula [high — operational]: The company's business plan is heavily reliant on the successful development and eventual commercialization of its standardized TCM formula for neurocognitive disorders. Any delays or failures in research, efficacy trials, or manufacturing could severely impact its prospects.
• Competitive and Regulatory Environment [medium — market]: Operating in the bioscience and TCM sector involves navigating a complex and competitive landscape. The success of the business plan is subject to the difficulties, complications, and delays frequently encountered in early-stage development within this environment.

Industry Context

Regencell operates in the bioscience sector, specifically focusing on Traditional Chinese Medicine (TCM) for neurocognitive disorders. This niche involves significant research and development investment, long product development cycles, and a complex regulatory pathway. The industry is characterized by a growing interest in alternative and complementary therapies, but also by the need for rigorous scientific validation and regulatory approval to gain mainstream acceptance.

Regulatory Implications

The company faces substantial regulatory hurdles as it has no approved products and no granted patents. Obtaining regulatory approval in jurisdictions like Hong Kong and potentially others is critical for commercialization. The lack of current approvals and patents represents a significant risk to its business model and future revenue generation.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: Fiscal Year End — Reported net losses of $3.58 million for the fiscal year.
• 2025-06-13: 38-for-1 Forward Stock Split — Increased outstanding ordinary shares to 494,488,908, impacting per-share metrics but not overall company valuation.
• 2024-06-30: Fiscal Year End — Reported net losses of $4.36 million for the fiscal year.
• 2021-07-16: Nasdaq Listing Date — Ordinary Shares began trading on the Nasdaq Capital Market, providing access to public capital markets.

Glossary

TCM

Traditional Chinese Medicine, a system of health care that originated in China and has been used for thousands of years. (Regencell is developing TCM formulas for specific medical conditions, which is the core of its business.)

Forward Stock Split

An action taken by a company to increase the number of its outstanding shares by dividing each existing share into multiple new shares. (Regencell executed a 38-for-1 forward stock split, significantly increasing its share count and affecting per-share calculations.)

Neurocognitive Disorders

Conditions that affect mental processes such as thinking, remembering, learning, and problem-solving. (Regencell's primary focus is on developing treatments for neurocognitive disorders like ADHD and ASD.)

Efficacy Trials

Clinical studies designed to determine if a treatment is effective and produces the desired results. (The company expects to incur research and development expenses for advancing its efficacy trials for its TCM formula.)

Year-Over-Year Comparison

For the fiscal year ended June 30, 2025, Regencell Bioscience Holdings Ltd reported a net loss of $3.58 million, a slight improvement from the $4.36 million net loss in the prior fiscal year. The company remains in an early-stage development phase with no revenue from product sales, and its operations continue to be funded by IPO proceeds. A significant event was the 38-for-1 forward stock split on June 13, 2025, which increased the number of outstanding shares but did not alter the company's fundamental financial position or authorized capital.

Key Financial Figures

• $0.00001 — Registered Ordinary shares, par value $0.00001 RGC The Nasdaq Stock Market LLC Secur
• $ — tive Officer ("CEO") and director; "US$," "$" or "US dollar" refers to the lega
• $1,000,000 — he authorized share capital remained as $1,000,000 divided into 100,000,000,000 Ordinary S
• $3.58 million — mation. We incurred total net losses of $3.58 million and $4.36 million, respectively, for th
• $4.36 m — d total net losses of $3.58 million and $4.36 million, respectively, for the fiscal yea

Filing Documents

• ea0260820-20f_regencell.htm (20-F) — 1736KB
• ea026082001ex1-1_regencell.htm (EX-1.1) — 555KB
• ea026082001ex2-2_regencell.htm (EX-2.2) — 16KB
• ea026082001ex8-1_regencell.htm (EX-8.1) — 6KB
• ea026082001ex12-1_regencell.htm (EX-12.1) — 16KB
• ea026082001ex12-2_regencell.htm (EX-12.2) — 16KB
• ea026082001ex13-1_regencell.htm (EX-13.1) — 6KB
• ea026082001ex13-2_regencell.htm (EX-13.2) — 6KB
• image_001.jpg (GRAPHIC) — 10KB
• ex1-1_001.jpg (GRAPHIC) — 14KB
• 0001213900-25-104686.txt ( ) — 7034KB
• rgc-20250630.xsd (EX-101.SCH) — 40KB
• rgc-20250630_cal.xml (EX-101.CAL) — 36KB
• rgc-20250630_def.xml (EX-101.DEF) — 227KB
• rgc-20250630_lab.xml (EX-101.LAB) — 429KB
• rgc-20250630_pre.xml (EX-101.PRE) — 244KB
• ea0260820-20f_regencell_htm.xml (XML) — 654KB

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK 104 ITEM 12.

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES

DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES 104 PART II ITEM 13. DEFAULTS, DIVIDEND ARREARAGES AND DELINQUENCIES 105 ITEM 14. MATERIAL MODIFICATIONS TO THE RIGHTS OF SECURITY HOLDERS AND USE OF PROCEEDS 105 ITEM 15.

CONTROLS AND PROCEDURES

CONTROLS AND PROCEDURES 105 ITEM 16A. AUDIT COMMITTEE FINANCIAL EXPERT 107 ITEM 16B. CODE OF ETHICS 107 ITEM 16C. PRINCIPAL ACCOUNTANT FEES AND SERVICES 107 ITEM 16D. EXEMPTIONS FROM THE LISTING STANDARDS FOR AUDIT COMMITTEES 108 ITEM 16E. PURCHASES OF EQUITY SECURITIES BY THE ISSUER AND AFFILIATED PURCHASERS 108 ITEM 16F. CHANGE IN REGISTRANT'S CERTIFYING ACCOUNTANT 108 ITEM 16G. CORPORATE GOVERNANCE 108 ITEM 16H. MINE SAFETY DISCLOSURE 108 ITEM 16I. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS 108 ITEM 16J. INSIDER TRADING POLICIES 108 ITEM 16K. CYBERSECURITY 109 PART III ITEM 17.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 110 ITEM 18.

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 110 ITEM 19. EXHIBITS 110

SIGNATURES

SIGNATURES 112 i INTRODUCTION Unless otherwise indicated, numerical figures included in this Annual Report on Form 20-F (the "Annual Report") have been subject to rounding adjustments. Accordingly, numerical figures shown as totals in various tables may not be arithmetic aggregations of the figures that precede them. For the sake of clarity, this Annual Report follows the English naming convention of first name followed by last name, regardless of whether an individual's name is Chinese or English. Certain market data and other statistical information contained in this Annual Report are based on information from independent industry organizations, publications, surveys and forecasts. Some market data and statistical information contained in this Annual Report are also based on management's estimates and calculations, which are derived from our review and interpretation of the independent sources listed above. While we believe such information is reliable, we have not independently verified any third-party information and our internal data has not been verified by any independent source. Unless otherwise indicated or the context requires otherwise, references in this Annual Report to: "China" or the "PRC" are to the People's Republic of China, excluding Taiwan and the special administrative regions of Hong Kong and Macau for the purposes of this Annual Report only; "Hong Kong" is to the Hong Kong Special Administrative Region of the People's Republic of China for the purposes of this Annual Report only; "HK$" or "Hong Kong dollar" refers to the legal currency of Hong Kong; "Regencell Bioscience Holdings Limited" or "Regencell" is to Regencell Bioscience Holdings Limited, a Cayman Islands exempted company incorporated under the laws of the Cayman Islands; "Regencell Bioscience Limited" is to Regencell Bioscience Limited, a Hong Kong limited liability company organized under the laws of Hong Kong and a wholly-owned subsidiary of Regencell Bioscienc

Risk Factors

Risk Factors You should carefully consider the following risk factors, together with all of the other information included in this Annual Report. Investment in our securities involves a high degree of risk. You should carefully consider the risks described below together with all of the other information included in this Annual Report before making an investment decision. The risks and uncertainties described below represent our known material risks to our business. If any of the following risks actually occurs, our business, financial condition or results of operations could suffer. In that case, you may lose all or part of your investment. 1 Risks Related to Our Financial Position and Need for Capital We are an early - stage TCM bioscience company with a limited operating history. We expect to incur additional losses in the future. We are an early-stage TCM bioscience company with a limited operating history that focuses on the research, development and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically Attention Deficit Hyperactivity Disorder ("ADHD") and Autism Spectrum Disorder ("ASD") with no currently approved products. To date, we have focused almost exclusively on developing our product candidates. We have funded our operations to date primarily through proceeds from our initial public offering of our Ordinary Shares. We have no saleable products and have not generated any revenue from product sales. We have incurred operating losses since our formation. We incurred total net losses of $3.58 million and $4.36 million, respectively, for the fiscal years ended June 30, 2025 and 2024. Substantially all of our operating losses resulted from costs incurred in connection with our development programs and from general and administrative costs. We expect to continue to incur research and development expenses in the future as we continue the advancement of our efficacy trials and as we potentially pursue a